Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Physostigmine→

Physostigmine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
57-47-6
Molecular formula
C15H21N3O2
Molecular weight
275.35 g/mol
Drug class
Reversible carbamate acetylcholinesterase inhibitorcentrally acting cholinergic agent
Mechanism of action
Reversibly inhibits acetylcholinesterase, increasing acetylcholine concentrations at central and peripheral cholinergic synapses. This can overcome muscarinic receptor blockade in anticholinergic toxicity.
Indications / reported uses
  • Reversal of clinically significant central anticholinergic toxicity, particularly delirium, in carefully selected patients under specialist toxicology guidance.
  • Ophthalmic use for selected glaucoma indications is historical or jurisdiction- and formulation-specific.

Sources: https://www.ontariopoisoncentre.ca/siteassets/pdfs/english/patient-care-resources-documents/physostigminesalicylate_20260506.pdf · https://www.ncbi.nlm.nih.gov/mesh/68010827/

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Reversible carbamate acetylcholinesterase inhibitor; centrally acting cholinergic agent

Mechanism of action

Reversibly inhibits acetylcholinesterase, increasing acetylcholine concentrations at central and peripheral cholinergic synapses. This can overcome muscarinic receptor blockade in anticholinergic toxicity.

General use cases

  • Reversal of clinically significant central anticholinergic toxicity, particularly delirium, in carefully selected patients under specialist toxicology guidance.
  • Ophthalmic use for selected glaucoma indications is historical or jurisdiction- and formulation-specific.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Physostigmine Environmental Risk Assessment (ERA) (the Physostigmine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.